NDA 022433 · Astrazeneca
Brilinta
Ticagrelor · Oral · P2Y12 Platelet Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: May 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Jul 20, 2011
Approved uses
7
Original approval plus efficacy supplements
Registered trials
486
104 Phase 3, 49 recruiting
FAERS reports
32,137
24,607 serious, 3,464 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: BLEEDING RISK • BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding ( 5.1 , 6.1 ). • Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage • ( 4.1 , 4.2 ). • Do not start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery (CABG) ( 5.1 , • 6.1 ). • If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of • subsequent cardiovascular events ( 5.2 ). WARNING: BLEEDING RISK See full prescribing information for complete boxed warning. • BRILINTA, like other antiplatelet agents, can cause significant, • sometimes fatal bleeding. ( 5.1 , 6.1 ) • Do not use BRILINTA in patients with active pathological • bleeding or a history of intracranial hemorrhage. ( 4.1 , 4.2 ) • Do not start BRILINTA in patients undergoing urgent coronary •...
What it is approved for
From the label in effect May 7, 2026.
BRILINTA is a P2Y 12 platelet inhibitor indicated • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) • to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) • to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) 1.1 Acute Coronary Syndrome or a History of Myocardial Infarction BRILINTA is indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS [see Clinical Studies (14.1) ] . 1.2 Coronary Artery Disease but No Prior Stroke or Myocardial Infarction BRILINTA is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical Studies (14.2) ] . While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). 1.3 Acute Ischemic Stroke or Transient Ischemic Attack (TIA) BRILINTA is indicated to reduce the risk of stroke in patients with acute...
Mechanism: Ticagrelor and its major metabolite reversibly interact with the platelet P2Y 12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 22, 2024 Supplement 35 · Efficacy LetterLabel
- May 9, 2022 Supplement 34 · Efficacy · priority review LetterLabel
- Nov 5, 2020 Supplement 29 · Efficacy · priority review LabelLetterReview
- May 28, 2020 Supplement 28 · Efficacy LabelLetterReview
- Apr 3, 2019 Supplement 23 · Efficacy LetterLabel
- Sep 3, 2015 Supplement 15 · Efficacy · priority review ReviewOtherLetter
- Jul 20, 2011 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
2 products under this application
- BRILINTA · TICAGRELOR 60MG · TABLET, ORAL · Prescription · TE AB
- BRILINTA · TICAGRELOR 90MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ticagrelor" as an intervention, any sponsor and status, largest first.
- Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of AspirinPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01225562 · 21,379 participants · Start Oct 2010 · Primary completion Dec 2014
Drug: Ticagrelor 90 mg; Ticagrelor 60 mg and 1 more · For: Myocardial Infarction; Cardiovascular Death; Atherothrombosis and 1 more
Sites: Alexander City, Alabama; Athens, Alabama; Birmingham, Alabama · 826 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- ACT-GLOBAL Adaptive Platform Trial for StrokePivotal-lookingRecruiting
The George InstituteAcademic, hospital or other
NCT06352632 · 20,000 participants (planned) · Start Sep 26, 2024 · Primary completion Sep 2034
Drug: Standard-dose intravenous tenecteplase; Low-dose intravenous tenecteplase and 9 more · For: Stroke
Sites: Sydney, Australia; Calgary, Canada
- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes MellitusPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01991795 · 19,271 participants · Start Feb 10, 2014 · Primary completion Jan 25, 2019
Drug: Ticagrelor 60 mg; Ticagrelor placebo · For: Diabetes Mellitus, Type 2
Sites: Alexander City, Alabama; Birmingham, Alabama; Fairhope, Alabama · 1,237 sites in all
- A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary SyndromePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00391872 · 18,624 participants · Start Oct 2006 · Primary completion Mar 2009
Drug: Ticagrelor; Clopidogrel · For: Acute Coronary Syndrome
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 672 sites in all
- Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary SyndromePivotal-lookingCompleted
Vastra Gotaland RegionGovernment (non-federal)
NCT05183178 · 17,095 participants · Start Feb 1, 2022 · Primary completion Aug 31, 2025
Drug: Prasugrel 10 mg p.o; Ticagrelor 90 mg · For: Acute Coronary Syndrome
Sites: Lund, Sweden
- GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent ImplantationPivotal-lookingCompleted
ECRI bvIndustry
NCT01813435 · 15,991 participants · Start Jul 1, 2013 · Primary completion Nov 9, 2015
Drug: Ticagrelor; Acetylsalicylic Acid and 1 more · For: Coronary Artery Disease (CAD)
Sites: Brisbane, Australia; Melbourne, Australia; Graz, Austria · 130 sites in all
- A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery DiseasePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01732822 · 13,885 participants · Start Dec 4, 2012 · Primary completion Sep 26, 2016
Drug: Ticagrelor; Clopidogrel · For: Peripheral Artery Disease
Sites: Alexander City, Alabama; Auburn, Alabama; Birmingham, Alabama · 776 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea4,051
- myocardial infarction2,804
- death1,733
- fatigue1,558
- off label use1,534
- chest pain1,485
- dizziness1,272
- contusion1,090
- drug interaction997
- asthenia937
- malaise899
- haemorrhage888
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 3 |
| 2009 | 8 |
| 2010 | 5 |
| 2011 | 52 |
| 2012 | 1,008 |
| 2013 | 1,229 |
| 2014 | 1,596 |
| 2015 | 2,107 |
| 2016 | 4,309 |
| 2017 | 3,151 |
| 2018 | 2,956 |
| 2019 | 2,251 |
| 2020 | 2,191 |
| 2021 | 2,195 |
| 2022 | 1,881 |
| 2023 | 2,106 |
| 2024 | 2,176 |
| 2025 | 1,702 |
| 2026 | 1,211 |
Recalls
2 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
May 25, 2017 · Class I · Terminated
Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Brilinta (Ticagrelor)
2024 spending
$685M
Beneficiaries
242,931
1,029,007 claims
Per beneficiary
$2,822
$7.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $588,513,924 |
| 2021 | $602,371,203 |
| 2022 | $638,382,092 |
| 2023 | $691,725,954 |
| 2024 | $685,497,437 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
Maqsood MH, Feit F, Kaul U, et al. · JAMA Cardiol 2026 · Systematic Review, Meta-Analysis
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Wallentin L, Becker RC, Budaj A, et al. · N Engl J Med 2009 · Comparative Study, Multicenter Study
- Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.
Jeppsson A, James S, Moller CH, et al. · N Engl J Med 2025 · Clinical Trial, Phase II, Comparative Study
- Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis.
Valgimigli M, Gragnano F, Branca M, et al. · JAMA Cardiol 2024 · Systematic Review, Meta-Analysis
- The MOVEMENT Trial.
Holm M, Tornvall P, Henareh L, et al. · J Am Heart Assoc 2019 · Multicenter Study, Randomized Controlled Trial
- Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis.
Lun R, Dhaliwal S, Zitikyte G, et al. · JAMA Neurol 2022 · Comparative Study, Systematic Review
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.